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Department of Biochemistry, McGill University, Montre´al, Que´bec, CanadaABSTRACT Although specific proteins have been identified that regulate the membrane association and facilitate intracellular
transport of prenylated Rho- and Rab-family proteins, it is not known whether cellular proteins fulfill similar roles for other pre-
nylated species, such as Ras-family proteins. We used a previously described method to evaluate how several cellular proteins,
previously identified as potential binding partners (but not effectors) of K-ras4B, influence the dynamics of K-ras association with
the plasma membrane. Overexpression of either PDEd or PRA1 enhances, whereas knockdown of either protein reduces, the
rate of dissociation of K-ras from the plasma membrane. Inhibition of calmodulin likewise reduces the rate of K-ras dissociation
from the plasma membrane, in this case in a manner specific for the activated form of K-ras. By contrast, galectin-3 specifically
reduces the rate of plasma membrane dissociation of activated K-ras, an effect that is blocked by the K-ras antagonist farne-
sylthiosalicylic acid (salirasib). Multiple cellular proteins thus control the dynamics of membrane association and intercompart-
mental movement of K-ras to an important degree even under basal cellular conditions.INTRODUCTIONMany prenylated proteins, including diverse members of the
Ras superfamily, move between different subcellular
compartments during posttranslational maturation and as
part of their normal biological function (1–3). The mecha-
nisms of intracellular transport of these proteins are only
partly understood, but they typically include at least some
steps based on nonvesicular as well as vesicular transport
through the cytoplasm. H- and N-ras, for example, can reach
the plasma membrane via either vesicular or nonvesicular
pathways (4,5), recycle from the plasma membrane to the
Golgi via a cytoplasmic intermediate (6,7), and have even
been identified in nonvesicular cytoplasmic ‘‘rasosomes’’
(2,8), whose role in their intracellular transport remains to
be clarified. K-ras4B utilizes nonvesicular pathways both
to reach the plasma membrane upon maturation and to
subsequently transfer between the plasma membrane and
other cellular compartments (3,4,9–14).
Proteins have been identified that mediate and regulate
intracellular transport of prenylated Rab- and Rho-family
G-proteins (e.g., RabGDI and RhoGDI (15–22)). This is
the case even for Rho-family proteins that by themselves
can dissociate from membranes at appreciable rates (19)
and for which chaperone proteins serve other roles, such
as modulating the kinetics of G-protein trafficking and
signaling or hindering G-protein association with inappro-
priate intracellular loci. To date, it remains unclear whether
cellular proteins also facilitate or regulate nonvesicular steps
in the intracellular traffic of different Ras proteins.
Using a novel fluorescent-microscopic method, we previ-
ously showed that although K-ras4B is predominantly asso-Submitted August 13, 2010, and accepted for publication October 4, 2010.
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conditions, it in fact cycles continuously on and off the
membrane on a timescale of minutes (14). Here, we apply
this method to assess how four proteins previously proposed
as potential K-ras chaperones influence the dynamics of the
K-ras/plasma membrane interaction. We show that three of
these species—PDEd (PrBP/d), prenylated Rab protein
acceptor protein 1 (PRA1, prenylin), and calmodulin
(11,23–26)—accelerate the rate of K-ras dissociation from
the plasma membrane, whereas a fourth K-ras-associating
protein—galectin-3 (27)—reduces the rate of release of
activated K-ras from the plasma membrane. Collectively,
these proteins strongly modulate the dynamics of plasma
membrane association and intercompartmental transfer of
K-ras within the cell.MATERIALS AND METHODS
Peptide synthesis and transfer measurements
Fluorescent prenylated peptides based on the membrane-targeting sequence
of N-ras (bimanylthioacetyl-GMCGLPC(prenyl)-OMe) and their S-acyl-
ated derivatives were synthesized as described previously (28). Large
unilamellar acceptor lipid vesicles, normally composed of 1-palmitoyl-2-
oleoyl phosphatidylcholine (POPC), were prepared by extruding
extensively dried/rehydrated lipid mixtures through 0.1-mm pore size poly-
carbonate filters in 100 mM KCl, 10 mM Mes, 0.1 mM EDTA, pH 6.0.
Donor vesicles were prepared similarly but incorporated 0.5 mol%
each of fluorescent peptide and the nonexchangeable quencher lipid
1-palmitoyl-2-(120-DABSyl-stearoyl)-phosphatidylcholine (29). Transfer
of peptides between vesicles was monitored by recording the time course
of fluorescence dequenching after mixing donor vesicles (30–150 mM)
with a 10-fold excess of acceptor vesicles as described previously (29).
The time courses of peptide transfer (when normalized to the peptide
concentration) were independent of the total vesicle concentration, confirm-
ing that transfer proceeded by dissociation/diffusion of peptide monomers
rather than through vesicle-vesicle interactions.doi: 10.1016/j.bpj.2010.10.001
3328 Bhagatji et al.Plasmid constructs
Bicistronic expression plasmids incorporating the coding sequences of
human PDEd, PRA1 or galectin-3 (flanked by EcoRI and BamHI sites) fol-
lowed by the internal ribosome entry site (nucleotides 259–836) of enceph-
alomyocarditis virus and the coding sequence of mCitrine (YFP), flanked
by BamHI and AflII sites and omitting the YFP initiator ATG codon,
were prepared from pcDNA3.1() (Invitrogen, Burlington, Canada) using
standard polymerase chain reaction (PCR) methods. Plasmids encoding
human PRA1 linked to an N-terminal HA-tag (MAYPYDVPDYASL-), or
amino acid residues 1–80 of human UDP-Gal:b-GlcNAc-b-1,4-galactosyl-
transferase 1 fused via a –GAKPPVSR– linker to YFP, were similarly
prepared by ligating appropriate PCR-derived sequences between the
EcoR1 and BamH1 sites of pcDNA3.1(). Plasmids encoding CFP-Kras,
FRB2-CFP-Kras, and FRB2-CFP–tK and their variant forms were prepared
as described previously (14), with a –YSDLELKLRILQTR-encoding linker
sequence between the CFP- (Cerulean-) and K-ras-encoding sequences.
Other plasmids used have been described previously (14).siRNA treatments and plasmid transfections
siRNAs with the following sense-strand sequences, and with unpaired 30-
dTdT extensions on each strand, were obtained from Dharmacon (Lafay-
ette, CO): for galectin-3, (species 1) TAACGCATCATGGAGCGTT and
(species 2) GAATGGTTCTTCGAGTTTG; for PDEd, (species 1) GAAC
GUUAUCAUAGAAACA and (species 2) GACGACGAUCUUCUU
GUAA; for PRA1, (species 1) TAGTACTCCACGTTGCGTA and
(species 2) UCUCGGCCAAAGAGCACAAGC; and for PRA2, UCAG
CAAAGUGAAGGAAUATT. An siRNA based on an inverted form of the
4E-T mRNA, CGUACCGUGGAAUAGUUCC (a gift from Dr. Nahum So-
nenberg, McGill University), was used as an irrelevant control. HeLa cells,
grown to 30–40% confluency on gelatin-coated glass-bottomed 2.5-cm
culture dishes, were incubated with 240 pmol of siRNA complexed to Oli-
gofectamine (Invitrogen) according to the manufacturer’s instructions.
Cells were transfected, using calcium phosphate, with plasmids encoding
the indicated proteins 24 h after siRNA treatment, then examined by fluo-
rescence microscopy 36–42 h thereafter. Galectin-3, PDEd, and PRA1 were
overexpressed by transfecting cells (using calcium phosphate) with bicis-
tronic plasmids encoding these proteins together with YFP, and the cells
were examined by fluorescence microscopy 40–48 h posttransfection.
HeLa cells stably expressing HA-tagged PRA1 were prepared by calcium
phosphate transfection and selection/propagation in medium containing
800 mg/mL Geneticin (Invitrogen).Microscopy
Cell monolayers were washed three times in Hank’s buffered saline con-
taining 25 mM HEPES, pH 7.0, before imaging. The kinetics of relocaliza-
tion of expressed fluorescent protein constructs from the plasma membrane
to mitochondria upon addition of rapamycin (500 nM or 2 mM, with compa-
rable results) in cells coexpressing mitoRFP-FKBP3 were determined by
wide-field fluorescence microscopy and quantitative image analysis (14).
A total of 25–70 cells were analyzed in three to five separate experiments
for each treatment. These experiments were carried out at 22C to suppress
potential contributions of vesicular trafficking processes to K-ras relocali-
zation (14). Confocal microscopy of cells fixed at 37C (3% paraformalde-
hyde in phosphate-buffered saline, 15 min) was also carried out as
described previously (14).Immunoblotting and qRT-PCR
Galectin-3 levels in cell samples (100 mg protein) were determined by
sodium dodecyl sulfate polyacrylamide gel electrophoresis, immunoblot-
ting, and densitometry, using as primary antibody a rabbit polyclonalBiophysical Journal 99(10) 3327–3335anti-galectin-3 IgG (H-160; Santa Cruz Biotechnology, Santa Cruz, CA).
Relative expression levels of mRNA encoding galectin-3, PDEd, PRA1,
or, as a reference, b-actin were determined for 400–500-ng RNA samples
(extracted from cells using Trizol reagent (Invitrogen)) by one-step quanti-
tative reverse-transcription (qRT-) PCR, using a Light Cycler apparatus and
the Light Cycler RNA master Sybr Green I kit (Roche Diagnostics Canada,
Laval, Canada) according to the manufacturer’s instructions. The following
forward and reverse-sense primers were used: for b-actin, 50-ACAG
CACTGTGTTGGCGTAC-30 and 50-TTCCTTCCTGGGCATGGAGT-30;
for galectin-3, 50-TGTGCCTTATAACCTGCCTTT-30 and 50-TTCTGTT
TGCATTGGGCTTCA-30; for PDEd, 50-ATGAACCTTCGGGATGCT
GAG-30 and 50-TTCTCGAGACACTGCCTTGCA-30; and for PRA1, 50-
ACGTGGAGTACTACCAGAGCA-30 and 50-ACTCCAAGGTGCGCAGA
TAGA-30.RESULTS
Kinetics of dissociation of farnesylated versus
geranylgeranylated peptides from lipid bilayers
To aid interpretation of the in vivo experiments described
further below, in initial experiments we compared the rates
of dissociation of fluorescent farnesylated versus geranyl-
geranylated peptides from lipid bilayers, as determined
from the rates of peptide transfer between lipid vesicles
(28–30). These experiments used prenylated peptides based
on the membrane-targeting sequence of N-ras, which is
more synthetically tractable than that of K-ras. We previ-
ously showed that the effects of farnesyl/geranylgeranyl
substitution on the interactions of prenylated peptides with
lipid bilayers are virtually independent of the peptide
sequence (31). N-ras, like K-ras, can exist in both farnesy-
lated and geranylgeranylated forms (32,33).
As shown in Fig. 1, A and B, at 37C the farnesylated
N-ras peptide transfers between POPC vesicles roughly
35-fold faster than its geranylgeranylated counterpart
(bilayer dissociation rate constants kd of 0.62 5 0.14 s
1
and 0.017 5 0.001 s1, respectively). The corresponding
values of kd for the two species at 22
C (0.1625 0.026 s1
and 0.00605 0.0010 s1) differ by a comparable factor.
The time courses of intervesicle transfer of the prenylated
N-ras peptides are biexponential (Fig. 1, A and B), suggest-
ing that peptide transbilayer diffusion partly rate-limits the
later stages of the process (28). Although our kinetic anal-
ysis takes account of this complication (see Supporting
Material), to avoid it entirely we also examined the interve-
sicle transfer of N-ras peptides that were both prenylated
and S-acylated. The time courses of transfer of these species
are slower and monoexponential (see Fig. 1 C), as expected
when dissociation from the vesicle outer surface is entirely
rate-limiting for transfer. As summarized in Fig. 1 D, at both
22C and 37C the dissociation rate constant for a given
farnesyl/S-acyl peptide is 30- to 35-fold larger than that
for the analogous geranylgeranylated species, similar to
the behavior observed for unacylated N-ras peptides. These
very large effects of geranylgeranyl/farnesyl substitution on
the rate constants for dissociation of prenylated peptides
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FIGURE 1 Kinetics of transfer of prenylated N-
ras peptides between lipid vesicles. (A–C) Time
courses of transfer of (A) farnesylated, (B) geranyl-
geranylated, and (C) farnesylated/C6-acylated
N-ras carboxy-terminal peptide from quencher-
containing to quencher-free lipid vesicles at
37C. Dashed curves represent the best monoexpo-
nential, and solid curves the best biexponential fits
to the time courses (including plateau regions not
shown for panels B and C). (D) First-order rate
constants determined for intervesicle transfer of
(C) farnesyl/S-acyl N-ras peptides at 37C, (B)
geranylgeranyl/S-acyl N-ras peptides at 37C,
(:) farnesyl/S-acyl N-ras peptides at 22C, and
(D) geranylgeranyl/S-octanoyl N-ras peptide at
22C. Values shown (mean5 SE) represent three
or more independent determinations in at least two
separate experiments.
Proteins Modulating K-ras Transport 3329from bilayers resemble in magnitude the effects of such
substitution on the equilibrium dissociation constants (Kd)
for bilayer binding of prenylated peptides (31). Ghomashchi
et al. (34) likewise found that the bilayer dissociation rates
for geranylgeranylated versus farnesylated versions of the
polybasic carboxy-terminal peptide of cdc42Hs differed
by a very large, though unquantitated, factor.Intracellular transfer rates of farnesyated versus
geranylgeranylated forms of K-ras
We previously showed that CFP-labeled K-Ras incorpo-
rating rapamycin-dependent heterodimerization domains
(FRB2-CFP-Kras– structure shown in Fig. 2 A) redistributes
from the plasma membrane to mitochondria, with kinetics
reflecting its rate of dissociation from the plasma
membrane, when rapamycin is added to cells that also
express a complementary binding partner (mitoFKBP3) on
their mitochondria (14). In HeLa cells this relocalization
process follows an exponential time course with a half-
time of roughly 2 min (Fig. 2 B). For both FRB2-CFP-
Kras and its tail-only (-tK) derivative incorporating the
K-ras membrane-targeting sequence alone, replacement of
the farnesyl group by a geranylgeranyl residue decreases
the rate constant for plasma membrane dissociation by2.5- to 3-fold (Fig. 2 C). The magnitude of this decrease
is far smaller than that observed above for dissociation of
geranylgeranylated versus farnesylated peptides from lipid
bilayers in vitro (30- to 35-fold), suggesting that release of
K-ras from the plasma membrane is not a purely sponta-
neous, unassisted process of dissociation from the
membrane bilayer.Intracellular proteins accelerate K-ras
dissociation from the plasma membrane
The intracellular proteins PDEd, PRA1, and calmodulin
have been shown to interact with K-ras or closely related
species in a prenylation-dependent manner (11,24–26,35–
37). We accordingly examined whether one or more of these
proteins could facilitate the intracellular transport of K-ras
in HeLa cells. In preliminary experiments we established
that localization of CFP-Kras (or FRB2-CFP-Kras) to the
plasma membrane is not discernibly altered by overexpres-
sion of PDEd or PRA1, or by cell treatment with PDEd or
PRA1-mRNA-directed siRNAs (Fig. S1), which reduce the
levels of mRNA encoding these proteins to <10% and
<20% of control values, respectively (Fig. S2 A). Simulta-
neous knockdown of PRA1 and PDEd moderately dimin-
ishes cell viability and modestly increases the level ofBiophysical Journal 99(10) 3327–3335
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FIGURE 2 (A) Structures of the novel rapamycin-binding K-ras-incorpo-
rating protein constructs utilized in this study. CFP-Kras and CFP-Kras
(GG) constructs were prepared omitting the rapamycin-binding FRB
modules. (B) Representative time courses measured for rapamycin-induced
relocalization of FRB2-CFP-Kras from the plasma membrane to mitochon-
dria in HeLa cells coexpressing the mitochondrial outer membrane-
anchored heterodimerization partner mitoRFP-FKBP3. Solid circles:
control cells; open circles: cells treated with anti-PDEd siRNA 24 h before
plasmid transfection; open triangles: cells cotransfected with a PDEd- and
Biophysical Journal 99(10) 3327–3335
3330 Bhagatji et al.intracellular CFP-Kras in some cells (Fig. S1 D). However,
in these cells the non-plasma membrane pool of K-ras did
not colocalize with either a Golgi (Fig. S1 D) or an endo-
plasmic reticulum (ER) marker (not shown). It thus appears
that PDEd or PRA1 can be strongly depleted without
compromising the transport of nascent K-ras from the ER
(where it receives posttranslational modifications critical
for its proper final localization (38–42)) to the plasma
membrane.
PDEd possesses a hydrophobic binding pocket that is
very similar to the prenyl-residue binding pocket of
RhoGDI and interacts with Rap and Ras proteins (among
other species) in a prenylation-dependent manner (26,36).
At very high expression levels, PDEd can partially shift
K-ras from the plasma membrane to the cytoplasm in
HEK 293 cells (26), although, as described above, we did
not observe this effect in our experimental system. As
shown in Figs. 2 B and 3 A, overexpression of PDEd mark-
edly enhances the rate of dissociation of FRB2-CFP-Kras,
its activated (G12V) and activation-resistant (S17N)
mutants, and, to a still greater extent, its geranylgeranylated
equivalent (–KR(GG)) from the plasma membrane. Similar
but smaller effects of PDEd overexpression are observed for
the tail-only –tK and –tK(GG) constructs. PDEd overexpres-
sion does not affect the rate of dissociation of a construct
targeted to the plasma membrane via a designed polyba-
sic/amphiphilic helical sequence (FRB2-CFP-amphi; struc-
ture shown in Fig. 2 A), indicating that the effects of
altered PDEd levels on plasma membrane dissociation of
K-ras are not a consequence of general changes in plasma
membrane physical properties such as surface charge.
siRNA-mediated knockdown of PDEd levels significantly
reduces the rate of dissociation of FRB2-CFP-Kras, its
G12Vand S17N variants, and its geranylgeranylated equiva-
lent from the plasmamembrane (Figs. 2 B and 3 A). Although
two different PDEd-directed siRNAs induced similar reduc-
tions in the rate of plasma membrane dissociation of FRB2-
CFP-Kras, an irrelevant control siRNA did not affect the rate
of release of this species or its G12V mutant from the plasma
membrane (Fig. 3 A). Moreover, expression of PDEd, from
a plasmid containing a knockdown-resistant PDEd coding
sequence, in cells treated with PDEd-directed siRNA restores
the rate of relocalization of FRB2-CFP-Kras to a level compa-
rable to that observed in cells treated with the PDEd-encoding
plasmid alone. These results argue that the effects of PDEd-
directed siRNAs on the rate of K-ras dissociation from the
plasma membrane are not due to off-target effects.YFP-encoding bicistronic plasmid. Data were fitted using the equation
x(t) ¼ A þ B exp(ktransfert), where A, B, and ktransfer are fitting constants.
(C) Rate constants ktransfer determined for rapamycin-induced redistribution
of FRB-CFP-Kras and related constructs from the plasma membrane to
mitochondria in HeLa cells coexpressing mitoRFP-FKBP3. Constructs
are denoted as follows: tK/tKGG ¼ FRB2-CFP-tK/-tKGG; KR/KRGG ¼
FRB2-CFP-Kras/Kras(GG); G12V, S17N ¼ mutant forms of FRB2-CFP-
Kras. Other experimental details are as described in Materials and Methods.
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FIGURE 3 Modulating cellular PDEd, PRA1, or
calmodulin levels alters the rate of dissociation of
K-ras-derived protein constructs from the plasma
membrane. Constructs are denoted as for Fig. 2
(and amphi ¼ FRB2-CFP-amphi). (A and B)
Effects of varying cellular levels of (A) PDEd or
(B) PRA1 on the dissociation rate constants for
the indicated constructs. Rates are normalized to
the corresponding rates measured for the same
constructs expressed (with mitoFKBP3) in other-
wise untreated cells. Cells were additionally trans-
fected with the indicated siRNAs or plasmids
(OE ¼ bicistronic vectors encoding PDEd (A) or
PRA1 (B) and YFP; siRNA/rescue ¼ anti-PDEd
or anti-PRA1 siRNA species 2 plus a bicistronic
plasmid encoding knockdown-resistant mRNAs
for the same proteins). (C) Effects of pretreatment
with the calmodulin inhibitor W-7 (100 mM,
30 min, 37C; black bars) or BAPTA-AM
(50 mM, 20 min, 37C; gray bars) on the rates of
rapamycin-induced redistribution of the indicated
constructs. Rates are normalized to those measured
for the same constructs in mock-pretreated cells.
(D) Effects of dual treatment of cells with anti-
PDEd and anti-PRA1 siRNAs (species 2 listed in
Materials and Methods), or with one of these
siRNAs plus W-7, on the rate of dissociation of
FRB2-CFP-Kras from the plasma membrane.
Treatments giving significantly different transfer
rates for control and treated samples (p < 0.05,
determined by a standard two-sided t-test) are indi-
cated by double asterisks. Other experimental
details are given in Materials and Methods.
Proteins Modulating K-ras Transport 3331PRA1 has been reported to interact not only with multiple
Rab proteins but also with various singly prenylated proteins
of the ras superfamily, including H-ras and Rap1a (24), in
a prenylation-dependent manner. It has variously been re-
ported to be present in the Golgi, late endosomes, exocytic
vesicles, and plasma membrane, and to be variably distrib-
uted between membrane and soluble fractions, in different
cell types (23,24,43,44). In HeLa cells we found that stably
expressed, HA-tagged PRA1 was recovered entirely in the
pellet fraction after cell disruption and high-speed centrifu-
gation (Fig. S3 A). AYFP-PRA1 fusion protein expressed at
low levels partly colocalized with both a Golgi marker and
a late endosomal marker (Fig. S3, B–G). Since the intracel-
lular distribution of YFP-PRA1 appeared more diffuse at
higher expression levels, for the PRA1-overexpression
experiments described below we examined cells that
showed only modest levels of plasmid-driven PRA1 expres-
sion (assessed by low levels of coexpression of YFP from
the bicistronic plasmid).
Overexpression of PRA1 enhances, and siRNA-mediated
knockdown of PRA1 significantly reduces, the rate of disso-
ciation of FRB2-CFP-Kras, its G12V and S17N mutant
forms, and its geranylgeranylated equivalent from the plasma
membrane (Fig. 3 B). Two different PRA1-directed siRNAs,but not an siRNA directed against the closely homologous
but differently (ER-) localized protein PRA2 (45), cause
similar reductions in the rate of plasma membrane disassoci-
ation of FRB2-CFP-Kras, and this effect is reversed by simul-
taneously expressing PRA1 from a plasmid that incorporates
a knockdown-resistant PRA1 coding sequence. These obser-
vations indicate that the effects of PRA1-directed siRNAs on
K-ras dissociation from the plasma membrane do not repre-
sent off-target effects. Modulation of PRA1 levels does not
alter the rates of relocalization of the tail-only FRB2-CFP-
tK construct or the polybasic/amphiphilic helix-anchored
CFP-FRB2-amphi construct, indicating that altered PRA1
levels do not influence the rate of FRB2-CFP-Kras dissocia-
tion by perturbing general plasma membrane properties such
as surface charge.
Calmodulin mediates redistribution of K-ras from the
plasma membrane to the Golgi compartment upon elevation
of intracellular calcium levels in cultured hippocampal
neurons (11) and interacts with K-ras in mouse fibroblasts
even in the quiescent state (46). As shown in Fig. 3 C, treat-
ment of HeLa cells with the calmodulin inhibitor W-7
substantially reduces the rates of rapamycin-induced disso-
ciation of FRB2-CFP-Kras, its geranylgeranylated equiva-
lent, and its activated G12V derivative from the plasmaBiophysical Journal 99(10) 3327–3335
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3332 Bhagatji et al.membrane, but has little effect on the dissociation rate for
the activation-resistant S17N mutant or the tail-only –tK
construct, consistent with the reported selectivity of calmod-
ulin for interaction with the activated form of K-ras (25).
The selectivity (and the direction) of these effects indicates
that they do not arise from W-7-induced modification of the
plasma membrane surface charge (47). Preincubation of
cells with a membrane-permeant derivative of the calcium
chelator BAPTA also reduced the rate of relocalization of
FRB2-CFP-Kras, but not that of the FRB2-CFP–tK construct
(Fig. 3 C, gray bars). These results indicate that even at
basal cytoplasmic calcium concentrations, calmodulin facil-
itates the dissociation of K-ras from the plasma membrane.
Simultaneous treatment of cells with siRNAs directed
against PDEd and PRA1 reduced the rate of dissociation
of FRB2-CFP-Kras from the plasma membrane to a greater
degree than did either siRNA alone (Fig. 3 D). Cells trans-
fected with siRNA directed against either PDEd or PRA1
and then acutely exposed to W-7 also showed a greater
reduction in the rate of K-ras dissociation from the plasma
membrane than did cells treated with either agent individu-
ally. The large (up to fivefold) reductions in the rate of K-ras
dissociation from the plasma membrane under these condi-
tions indicate that these proteins collectively play a major
role in K-ras cycling off the plasma membrane, even under
basal cellular conditions.k d
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FIGURE 4 (A) Confocal scanning images of HeLa cells expressing CFP-
Kras and treated with galectin-3-directed siRNA (species 1 indicated in
Materials and Methods). (B) Confocal image of cells expressing CFP-
Kras together with galectin-3 (the latter from a bicistronic vector also
encoding YFP (inset) as a transfection marker). (C) Effects of galectin-3-
directed siRNAs (gray bars and black bars: species 1 and 2, respectively;
see Materials and Methods) or overexpression of galectin-3 (open bars)
on the rates of dissociation of FRB2-CFP-Kras and various derivatives
from the plasma membrane. (D) Enhancement of the rate of dissociation
of FRB2-CFP-Kras(G12V) from the plasma membrane by FTS at the indi-
cated concentrations. (E) Rate constant for dissociation of FRB2-CFP-Kras
(G12V) from the plasma membrane (normalized to the value measured for
control cells) in the absence (open bars) or presence (black bars) of 20 mM
FTS for cells transfected as indicated to modulate galectin-3 levels (OE ¼
overexpression, KD ¼ knockdown). Other experimental details are
described in Materials and Methods.Galectin-3 inhibits dissociation of activated K-ras
from the plasma membrane and is targeted by
farnesylthiosalicylic acid
Galectin-3 associates preferentially with the activated form
of K-ras through an interaction that appears to include
binding of the K-ras farnesyl group to a hydrophobic pocket
in galectin-3 (27,48). We therefore examined whether
altering intracellular levels of galectin-3 would affect the
kinetics of K-ras dissociation from the plasma membrane.
Neither siRNA-mediated reduction of galectin-3 levels (to
<5% of control values, as assessed by immunoblotting
(Fig. S2 B)) nor overexpression of the protein substantially
perturbed the plasma membrane localization of CFP-Kras or
FKB2-CFP-Kras (Fig. 4, A and B, and Fig. S1 J). However,
reduction of galectin-3 levels significantly increased the rate
of rapamycin-induced redistribution of FRB2-CFP-Kras, its
geranylgeranylated form, and its activated G12V mutant
from the plasma membrane (Fig. 4 C), though not that of
the activation-resistant S17N mutant or the tail-only
FRB2-CFP-tK or –tK(GG) constructs. Conversely, overex-
pression of galectin-3 decreased the rate of transfer of
FRB2-CFP-Kras and –Kras(G12V) from the plasma
membrane without affecting the rates of transfer of the
S17N mutant, the tail-only –tK construct, or the polyba-
sic/amphiphilic helix-targeted FRB2-CFP-amphi construct.
The anti-Ras agent S-farnesylthiosalicylic acid (FTS, sal-
irasib) enhances both the rate of lateral diffusion of activatedBiophysical Journal 99(10) 3327–3335K-ras on the plasma membrane and the rate of K-ras degra-
dation, potentially by inhibiting the farnesylation-dependent
interaction of K-ras with specific membrane-associated
proteins (49,50). As illustrated in Fig. 4 D, acute cell treat-
ment with FTS up to 10–20 mMmarkedly increases the rate
constant for dissociation of FRB2-CFP-K-ras(G12V) from
the plasma membrane, though this effect declines at higher
Proteins Modulating K-ras Transport 3333FTS concentrations. By contrast, FTS (20 mM) has no
significant effect on the rate of plasma membrane dissocia-
tion of FRB2-CFP-K-ras(G12V) in cells treated with galec-
tin-3-directed siRNA (Fig. 4 E). Conversely, in cells
overexpressing galectin-3, the effect of FTS is substantially
larger than in control cells. The rate of release of activated
K-ras from the plasma membrane, which in the absence of
FTS varies strongly (and inversely) with the level of galec-
tin-3 expression, thus becomes essentially independent of
the level of galectin-3 expression in FTS-treated cells. The
most parsimonious explanation for this result is that FTS
inhibits the association of activated K-ras with galectin-3
by competing for the farnesyl residue-binding pocket of
the latter protein (48).DISCUSSION
Although specific proteins have been shown to facilitate and
regulate the intracellular transport of Rab- and Rho-family
proteins (17,21,22), it remains unclear whether cellular
proteins similarly influence the nonvesicular transport of
other prenylated proteins. K-ras4B offers an interesting
case in point, given both its key roles in cellular signaling
and its observed transfer from the plasma membrane to
other cellular loci to mediate different signaling events
(11–13). Our results indicate that cellular proteins play
important roles in facilitating and regulating the dissociation
of K-ras from the plasma membrane, a process whose
kinetics may influence those of cellular signaling processes
in which K-ras redistributes between different cellular
compartments (10–13).
In vitro, geranylgeranylated peptides dissociate from lipid
bilayers at rates 30- to 35-fold slower compared to their far-
nesylated equivalents. By contrast, within cells geranylger-
anylated K-ras- or K-ras tail-based constructs dissociate
from the plasma membrane only 2.5- to 3-fold more slowly
than the corresponding farnesylated species, recalling
a previous finding (7) that farnesylated versus geranylger-
anyl-modified forms of GFP differ by only ~2.5-fold in their
rates of diffusion between intracellular membranes. This
result suggests that membrane dissociation and intercom-
partmental transfer of K-ras (and possibly of other preny-
lated species outside the Rho and Rab families) proceeds
largely through the mediation of cellular proteins, not
through a simple process of unassisted desorption/diffusion.
This proposal is supported by our findings that PDEd,
PRA1, and calmodulin substantially enhance the rate of
dissociation of K-ras (in its farnesylated or geranylgerany-
lated forms) from the plasma membrane. The collective
action of these proteins (and potentially of additional
cellular proteins as well) in facilitating release of K-ras
from the plasma membrane may play a particularly impor-
tant role in maintaining the normal or oncogenic functions
of K-ras when it is geranylgeranylated, as occurs in cells
treated with farnesyltransferase inhibitors (32,33).Both PDEd and calmodulin have been reported to extract
K-ras from membranes under certain conditions (11,26,37),
and both possess hydrophobic binding pockets that may
sequester the K-ras prenyl group within a soluble complex
(26,36,51). It might appear that these properties would
automatically confer on PDEd and calmodulin an ability
to accelerate dissociation of K-ras from the plasma
membrane. However, this is not inherently the case.
RhoGDI, for example, readily forms soluble complexes
with Rho-family proteins, but does not accelerate their
dissociation from membranes in either in vivo or model
systems (15,16,19,52). Our results suggest rather that
PDEd and calmodulin initially interact with K-ras at the
plasma membrane, lowering the kinetic barrier for K-ras
dissociation from the membrane, after which they may act
as cytoplasmic carriers for the protein as well. PDEd and
calmodulin may interact with K-ras at the plasma
membrane to weaken electrostatic and/or hydrophobic
interactions of the latter with the membrane in the transition
state for the desorption process, thereby lowering the acti-
vation energy and accelerating the rate of this process.
Calmodulin was previously shown to accelerate the release
of a MARCKS protein-derived amphiphilic/polybasic
sequence from lipid bilayers by such a mechanism (53).
Our observation that calmodulin inhibition alters the rate
of plasma membrane dissociation only for wild-type and
constitutively active (G12V) K-ras, whereas modulation
of PDEd levels alters as well the rate of dissociation of
the activation-resistant S17N mutant, are also consistent
with this proposed mechanism: the K-ras/calmodulin inter-
action, but not the PDEd/ras interaction, is ras activation-
dependent (26,35).
PRA1 was previously proposed to facilitate the intracel-
lular trafficking of ras proteins based on observations that
ras, as well as other prenylated proteins of the ras super-
family, interacts with PRA1 in mammalian cells (24). In
agreement with this proposal, we find that modulation of
cellular PRA1 levels markedly alters the kinetics of dissoci-
ation of K-ras from the plasma membrane. Given the exclu-
sive membrane localization that we observe by cell
fractionation for epitope-tagged PRA1 in HeLa cells,
PRA1 appears unlikely to function as a cytoplasmic carrier
for K-ras. However, as discussed above, such an ability is
neither sufficient nor necessary for a protein to accelerate
dissociation of K-ras from the plasma membrane. Instead,
PRA1 may interact with K-ras at the membrane, possibly
acting together with other proteins, to reduce the activation
energy for K-ras/membrane dissociation. Further study will
be required to elucidate whether modulating cellular PRA1
levels influences the rate of K-ras dissociation from the
plasma membrane by this or by other mechanisms.
Although in principle galectin-3 might function as a K-ras
chaperone by sequestering the K-ras farnesyl group (8),
in situ it appears to function primarily to restrain dissocia-
tion of activated K-ras from the plasma membrane. ThisBiophysical Journal 99(10) 3327–3335
3334 Bhagatji et al.finding is consistent with previous findings that galectin-3
interacts selectively with the activated form of K-ras (27)
and contributes to formation of short-lived K-ras nanoclus-
ters at the plasma membrane (48,54–57). If we assume that
K-ras cannot dissociate from the plasma membrane while
associated with nanoclusters, our observation that suppres-
sion of galectin-3 expression increases the rate of plasma
membrane dissociation of K-ras(G12V) by (2.1 5 0.2)-
fold (Fig. 4 C) suggests that at normal levels of galectin-3
expression, roughly one-half (52 5 5%) of activated
K-ras at the plasma membrane is present in nanoclusters
at any instant. A similar figure (44% of activated K-ras in
nanoclusters) was determined from direct immunogold/
electron microscopy measurements of the distribution of
K-ras(G12V) in BHK cell plasma membranes (56).
Our finding that the anti-Ras agent FTS accelerates the
release of activated K-ras from the plasma membrane to
an extent that varies directly with the level of galectin-3
expression indicates that FTS blocks the normal action of
galectin-3 to stabilize activated K-ras on the plasma
membrane. This activity of FTS may be related to its ability
to enhance the rate of cellular degradation of activated
K-ras, but not that of unprenylated forms of the protein
(50). Taken together, our findings strongly support previous
proposals that galectin-3 constitutes a central and essential
element in forming and stabilizing K-ras nanoclusters at
the plasma membrane (48,56), and suggest that galectin-3
is a direct target of the K-ras-antagonizing activity of
FTS, most plausibly by competition between FTS and
K-ras for a predicted prenyl residue-binding pocket in galec-
tin-3 (8,27,48,54). Given the central role of nanoclustering
in K-ras signaling at the plasma membrane (58), this action
of FTS would offer a mechanism for acute inhibition of
K-ras signaling activity as well as for the observed reduction
of K-ras stability on longer timescales (50).SUPPORTING MATERIAL
Three figures are available at http://www.biophysj.org/biophysj/supplemental/
S0006-3495(10)01216-6.
This research was supported by an operating grant from the Canadian Insti-
tutes of Health Research (CIHR) to J.R.S., by scholarship support to P.B.
from the CIHR Strategic Training Initiative in Chemical Biology, and by
support to C.L. from a CIHR operating grant to Dr. Jerry Pelletier (Depart-
ment of Biochemistry, McGill University).REFERENCES
1. Silvius, J. R. 2002. Mechanisms of Ras protein targeting in mammalian
cells. J. Membr. Biol. 190:83–92.
2. Ashery, U., O. Yizhar,., Y. Kloog. 2006. Nonconventional trafficking
of Ras associated with Ras signal organization. Traffic. 7:119–126.
3. Wright, L. P., and M. R. Philips. 2006. Thematic review series: lipid
posttranslational modifications. CAAX modification and membrane
targeting of Ras. J. Lipid Res. 47:883–891.Biophysical Journal 99(10) 3327–33354. Choy, E., V. K. Chiu, ., M. R. Philips. 1999. Endomembrane traf-
ficking of ras: the CAAX motif targets proteins to the ER and Golgi.
Cell. 98:69–80.
5. Zheng, H., J. McKay, and J. E. Buss. 2007. H-Ras does not need COP I-
or COP II-dependent vesicular transport to reach the plasma
membrane. J. Biol. Chem. 282:25760–25768.
6. Rocks, O., A. Peyker,., P. I. Bastiaens. 2005. An acylation cycle regu-
lates localization and activity of palmitoylated Ras isoforms. Science.
307:1746–1752.
7. Goodwin, J. S., K. R. Drake,., A. K. Kenworthy. 2005. Depalmitoy-
lated Ras traffics to and from the Golgi complex via a nonvesicular
pathway. J. Cell Biol. 170:261–272.
8. Ashery, U., O. Yizhar,., Y. Kloog. 2006. Spatiotemporal organization
of Ras signaling: rasosomes and the galectin switch. Cell. Mol. Neuro-
biol. 26:471–495.
9. Apolloni, A., I. A. Prior,., J. F. Hancock. 2000. H-ras but not K-ras
traffics to the plasma membrane through the exocytic pathway. Mol.
Cell. Biol. 20:2475–2487.
10. Roy, S., B. Wyse, and J. F. Hancock. 2002. H-Ras signaling and K-Ras
signaling are differentially dependent on endocytosis. Mol. Cell. Biol.
22:5128–5140.
11. Fivaz, M., and T. Meyer. 2005. Reversible intracellular translocation of
KRas but not HRas in hippocampal neurons regulated by Ca2þ/calmod-
ulin. J. Cell Biol. 170:429–441.
12. Bivona, T. G., S. E. Quatela, ., M. R. Philips. 2006. PKC regulates
a farnesyl-electrostatic switch on K-Ras that promotes its association
with Bcl-XL on mitochondria and induces apoptosis. Mol. Cell.
21:481–493.
13. Feig, L. A. 2006. The odyssey of K-ras. Mol. Cell. 21:447–449.
14. Silvius, J. R., P. Bhagatji,., D. Terrone. 2006. K-ras4B and prenylated
proteins lacking ‘‘second signals’’ associate dynamically with cellular
membranes. Mol. Biol. Cell. 17:192–202.
15. Regazzi, R., A. Kikuchi, ., C. B. Wollheim. 1992. The small GTP-
binding proteins in the cytosol of insulin-secreting cells are complexed
to GDP dissociation inhibitor proteins. J. Biol. Chem. 267:17512–
17519.
16. Bourmeyster, N., P. Boquet, and P. V. Vignais. 1994. Role of bound
GDP in the stability of the rho A-rho GDI complex purified from
neutrophil cytosol. Biochem. Biophys. Res. Commun. 205:174–179.
17. Pfeffer, S. R., A. B. Dirac-Svejstrup, and T. Soldati. 1995. Rab GDP
dissociation inhibitor: putting rab GTPases in the right place. J. Biol.
Chem. 270:17057–17059.
18. Ugolev, Y., Y. Berdichevsky, ., E. Pick. 2008. Dissociation of Rac1
(GDP).RhoGDI complexes by the cooperative action of anionic lipo-
somes containing phosphatidylinositol 3,4,5-trisphosphate, Rac
guanine nucleotide exchange factor, and GTP. J. Biol. Chem.
283:22257–22271.
19. Johnson, J. L., J. W. Erickson, and R. A. Cerione. 2009. New insights
into how the Rho guanine nucleotide dissociation inhibitor regulates
the interaction of Cdc42 with membranes. J. Biol. Chem. 284:23860–
23871.
20. Hoffman, G. R., N. Nassar, and R. A. Cerione. 2000. Structure of the
Rho family GTP-binding protein Cdc42 in complex with the multifunc-
tional regulator RhoGDI. Cell. 100:345–356.
21. Michaelson, D., J. Silletti,., M. R. Philips. 2001. Differential locali-
zation of Rho GTPases in live cells: regulation by hypervariable
regions and RhoGDI binding. J. Cell Biol. 152:111–126.
22. Seabra, M. C., and C. Wasmeier. 2004. Controlling the location and
activation of Rab GTPases. Curr. Opin. Cell Biol. 16:451–457.
23. Hutt, D. M., L. F. Da-Silva, ., J. K. Ngsee. 2000. PRA1 inhibits the
extraction of membrane-bound rab GTPase by GDI1. J. Biol. Chem.
275:18511–18519.
24. Figueroa, C., J. Taylor, and A. B. Vojtek. 2001. Prenylated Rab
acceptor protein is a receptor for prenylated small GTPases. J. Biol.
Chem. 276:28219–28225.
Proteins Modulating K-ras Transport 333525. Villalonga, P., C. Lo´pez-Alcala´,., N. Agell. 2001. Calmodulin binds
to K-Ras, but not to H- or N-Ras, and modulates its downstream
signaling. Mol. Cell. Biol. 21:7345–7354.
26. Nancy, V., I. Callebaut, ., J. de Gunzburg. 2002. The d subunit of
retinal rod cGMP phosphodiesterase regulates the membrane associa-
tion of Ras and Rap GTPases. J. Biol. Chem. 277:15076–15084.
27. Elad-Sfadia, G., R. Haklai,., Y. Kloog. 2004. Galectin-3 augments K-
Ras activation and triggers a Ras signal that attenuates ERK but not
phosphoinositide 3-kinase activity. J. Biol. Chem. 279:34922–34930.
28. Schroeder, H., R. Leventis, ., J. R. Silvius. 1997. S-Acylation and
plasma membrane targeting of the farnesylated carboxyl-terminal
peptide of N-ras in mammalian fibroblasts. Biochemistry. 36:
13102–13109.
29. Shahinian, S., and J. R. Silvius. 1995. Doubly-lipid-modified protein
sequence motifs exhibit long-lived anchorage to lipid bilayer
membranes. Biochemistry. 34:3813–3822.
30. Nichols, J. W., and R. E. Pagano. 1981. Kinetics of soluble lipid mono-
mer diffusion between vesicles. Biochemistry. 20:2783–2789.
31. Silvius, J. R., and F. l’Heureux. 1994. Fluorimetric evaluation of the
affinities of isoprenylated peptides for lipid bilayers. Biochemistry.
33:3014–3022.
32. Rowell, C. A., J. J. Kowalczyk,., A. M. Garcia. 1997. Direct demon-
stration of geranylgeranylation and farnesylation of Ki-Ras in vivo. J.
Biol. Chem. 272:14093–14097.
33. Whyte, D. B., P. Kirschmeier,., J. K. Pai. 1997. K- and N-Ras are ger-
anylgeranylated in cells treated with farnesyl protein transferase inhib-
itors. J. Biol. Chem. 272:14459–14464.
34. Ghomashchi, F., X. Zhang, ., M. H. Gelb. 1995. Binding of preny-
lated and polybasic peptides to membranes: affinities and intervesicle
exchange. Biochemistry. 34:11910–11918.
35. Lopez-Alcala´, C., B. Alvarez-Moya,., N. Agell. 2008. Identification
of essential interacting elements in K-Ras/calmodulin binding and its
role in K-Ras localization. J. Biol. Chem. 283:10621–10631.
36. Hanzal-Bayer, M., L. Renault,., R. C. Hillig. 2002. The complex of
Arl2-GTP and PDE d: from structure to function. EMBO J. 21:
2095–2106.
37. Sidhu, R. S., R. R. Clough, and R. P. Bhullar. 2003. Ca2þ/calmodulin
binds and dissociates K-RasB from membrane. Biochem. Biophys.
Res. Commun. 304:655–660.
38. Dai, Q., E. Choy,., M. R. Philips. 1998. Mammalian prenylcysteine
carboxyl methyltransferase is in the endoplasmic reticulum. J. Biol.
Chem. 273:15030–15034.
39. Schmidt, W. K., A. Tam, ., S. Michaelis. 1998. Endoplasmic retic-
ulum membrane localization of Rce1p and Ste24p, yeast proteases
involved in carboxyl-terminal CAAX protein processing and amino-
terminal a-factor cleavage. Proc. Natl. Acad. Sci. USA. 95:11175–
11180.
40. Bergo, M. O., G. K. Leung,., S. G. Young. 2000. Targeted inactiva-
tion of the isoprenylcysteine carboxyl methyltransferase gene causes
mislocalization of K-Ras in mammalian cells. J. Biol. Chem.
275:17605–17610.
41. Bergo, M. O., P. Ambroziak, ., S. G. Young. 2002. Absence of the
CAAX endoprotease Rce1: effects on cell growth and transformation.
Mol. Cell. Biol. 22:171–181.42. Chiu, V. K., J. Silletti,., M. H. Pillinger. 2004. Carboxyl methylation
of Ras regulates membrane targeting and effector engagement. J. Biol.
Chem. 279:7346–7352.
43. Fenster, S. D., W. J. Chung,., C. C. Garner. 2000. Piccolo, a presyn-
aptic zinc finger protein structurally related to bassoon. Neuron. 25:
203–214.
44. Sivars, U., D. Aivazian, and S. R. Pfeffer. 2003. Yip3 catalyses the
dissociation of endosomal Rab-GDI complexes. Nature. 425:856–859.
45. Abdul-Ghani, M., P.-Y. Gougeon,., J. K. Ngsee. 2001. PRA isoforms
are targeted to distinct membrane compartments. J. Biol. Chem.
276:6225–6233.
46. Liao, J., S. M. Planchon,., A. Wolfman. 2006. Growth factor-depen-
dent AKT activation and cell migration requires the function of c-K
(B)-Ras versus other cellular ras isoforms. J. Biol. Chem. 281:
29730–29738.
47. Sengupta, P., M. J. Ruano, ., A. Villalobo. 2007. Membrane-perme-
able calmodulin inhibitors (e.g. W-7/W-13) bind to membranes,
changing the electrostatic surface potential: dual effect of W-13 on
epidermal growth factor receptor activation. J. Biol. Chem.
282:8474–8486.
48. Shalom-Feuerstein, R., S. J. Plowman,., Y. Kloog. 2008. K-ras nano-
clustering is subverted by overexpression of the scaffold protein galec-
tin-3. Cancer Res. 68:6608–6616.
49. Niv, H., O. Gutman, ., Y. Kloog. 1999. Membrane interactions of
a constitutively active GFP-Ki-Ras 4B and their role in signaling.
Evidence from lateral mobility studies. J. Biol. Chem. 274:1606–1613.
50. Elad, G., A. Paz, ., Y. Kloog. 1999. Targeting of K-Ras 4B by S-
trans,trans-farnesyl thiosalicylic acid. Biochim. Biophys. Acta. 1452:
228–242.
51. Matsubara, M., T. Nakatsu,., H. Taniguchi. 2004. Crystal structure of
a myristoylated CAP-23/NAP-22 N-terminal domain complexed with
Ca2þ/calmodulin. EMBO J. 23:712–718.
52. Moissoglu, K., B. M. Slepchenko, ., M. A. Schwartz. 2006. In vivo
dynamics ofRac-membrane interactions.Mol. Biol. Cell. 17:2770–2779.
53. Arbuzova, A., D. Murray, and S. McLaughlin. 1998. MARCKS,
membranes, and calmodulin: kinetics of their interaction. Biochim. Bi-
ophys. Acta. 1376:369–379.
54. Shalom-Feuerstein, R., T. Cooks,., Y. Kloog. 2005. Galectin-3 regu-
lates a molecular switch from N-Ras to K-Ras usage in human breast
carcinoma cells. Cancer Res. 65:7292–7300.
55. Murakoshi, H., R. Iino,., A. Kusumi. 2004. Single-molecule imaging
analysis of Ras activation in living cells. Proc. Natl. Acad. Sci. USA.
101:7317–7322.
56. Plowman, S. J., C. Muncke,., J. F. Hancock. 2005. H-ras, K-ras, and
inner plasma membrane raft proteins operate in nanoclusters with
differential dependence on the actin cytoskeleton. Proc. Natl. Acad.
Sci. USA. 102:15500–15505.
57. Tian, T., S. J. Plowman, ., J. F. Hancock. 2010. Mathematical
modeling of K-Ras nanocluster formation on the plasma membrane.
Biophys. J. 99:534–543.
58. Tian, T., A. Harding,., J. F. Hancock. 2007. Plasma membrane nano-
switches generate high-fidelity Ras signal transduction. Nat. Cell Biol.
9:905–914.Biophysical Journal 99(10) 3327–3335
